グリオブラストーマ・マルチフォームにおけるロング・ノンコーディングRNAの干渉:次世代の治療法の主要標的
Soushruti Sarkar1, Subhrangsu Chatterjee1
1Department of Biological Sciences, Bose Institute, Kolkata 700091, India.
Drug discovery today
|February 21, 2026
まとめ
長いノンコーディングRNAは,多型膠芽細胞腫 (GBM) の発症と薬剤耐性において極めて重要です. これらのRNAを標的にすることは,この攻撃的な脳腫瘍に対する新しい治療戦略を提供します.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 遺伝学 遺伝学とは
背景:
- グリオブラストーマ・マルチフォーム (GBM) は,患者の生存率が低い,攻撃的な脳腫瘍です.
- 制御不能な進行と治療抵抗は,GBMの予後不良に寄与する.
研究 の 目的:
- グリオブラストーマ・マルチフォーム (GBM) の病原性におけるロング・ノンコーディングRNA (lncRNA) の役割を検討する.
- GBMの幹部,増殖,血管新生,治療抵抗に対する lncRNAsの影響を調査する.
- GBMにおけるlncRNAの治療ターゲティングについて議論します.
主な方法:
- GBMにおけるlncRNAに焦点を当てた文献レビュー.
- 薬剤耐性におけるlncRNAメカニズムの分析.
- lncRNAsを含む組み合わせ治療戦略の検討.
主要な成果:
- lncRNAsは,GBMの幹部,遺伝子発現,増殖,血管新生,および治療に対する耐性を著しく影響する.
- lncRNAsは,薬剤耐性を促す細胞経路を変更する.
- lncRNAは組織特異的な発現を示し,体液に持続する.
結論:
- lncRNAは,GBMの病原性および薬剤耐性における重要な役割を果たしています.
- lncRNAを標的にすることは,GBMに対する有望な治療法である.
- lncRNAsを含む組み合わせ治療は,GBMにおける治療結果を改善する可能性があります.
キーワード:
グリオブラストは多形である.がん がん がん がん がん がん がんロング・ノンコーディングRNAmRNAはmRNAというものです.miRNA スポンジングテモゾロミド (Temozolomide) とは テモゾロミド (Temozolomide) とは テモゾロミド (Temozolomide) とは テモゾロミド (Temozo) とは腫瘍 腫瘍 腫瘍 腫瘍さらに関連する動画
関連する概念動画
lncRNA - Long Non-coding RNAs
10.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
lncRNA - Long Non-coding RNAs
3.7K
3.7K
Experimental RNAi
8.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.0K
MicroRNAs
4.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.1K
MicroRNAs
24.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.4K
RNA Interference
28.2K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.2K


